Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest.
Biomarkers
GFAP
Heart arrest
In-hospital cardiac arrest
Out-of-hospital cardiac arrest
Prognostication
Tau
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
30
12
2023
accepted:
23
03
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
9
4
2024
Statut:
epublish
Résumé
The purpose was to evaluate glial fibrillary acidic protein (GFAP) and total-tau in plasma as predictors of poor neurological outcome after out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA), including comparisons with neurofilament light (NFL) and neuron-specific enolase (NSE). Retrospective multicentre observational study of patients admitted to an intensive care unit (ICU) in three hospitals in Sweden 2014-2018. Blood samples were collected at ICU admission, 12 h, and 48 h post-cardiac arrest. Poor neurological outcome was defined as Cerebral Performance Category 3-5 at 2-6 months after cardiac arrest. Plasma samples were retrospectively analysed for GFAP, tau, and NFL. Serum NSE was analysed in clinical care. Prognostic performances were tested with the area under the receiver operating characteristics curve (AUC). Of the 428 included patients, 328 were OHCA, and 100 were IHCA. At ICU admission, 12 h and 48 h post-cardiac arrest, GFAP predicted neurological outcome after OHCA with AUC (95% CI) 0.76 (0.70-0.82), 0.86 (0.81-0.90) and 0.91 (0.87-0.96), and after IHCA with AUC (95% CI) 0.77 (0.66-0.87), 0.83 (0.74-0.92) and 0.83 (0.71-0.95). At the same time points, tau predicted outcome after OHCA with AUC (95% CI) 0.72 (0.66-0.79), 0.75 (0.69-0.81), and 0.93 (0.89-0.96) and after IHCA with AUC (95% CI) 0.61 (0.49-0.74), 0.68 (0.56-0.79), and 0.77 (0.65-0.90). Adding the change in biomarker levels between time points did not improve predictive accuracy compared to the last time point. In a subset of patients, GFAP at 12 h and 48 h, as well as tau at 48 h, offered similar predictive value as NSE at 48 h (the earliest time point NSE is recommended in guidelines) after both OHCA and IHCA. The predictive performance of NFL was similar or superior to GFAP and tau at all time points after OHCA and IHCA. GFAP and tau are promising biomarkers for neuroprognostication, with the highest predictive performance at 48 h after OHCA, but not superior to NFL. The predictive ability of GFAP may be sufficiently high for clinical use at 12 h after cardiac arrest.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose was to evaluate glial fibrillary acidic protein (GFAP) and total-tau in plasma as predictors of poor neurological outcome after out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA), including comparisons with neurofilament light (NFL) and neuron-specific enolase (NSE).
METHODS
METHODS
Retrospective multicentre observational study of patients admitted to an intensive care unit (ICU) in three hospitals in Sweden 2014-2018. Blood samples were collected at ICU admission, 12 h, and 48 h post-cardiac arrest. Poor neurological outcome was defined as Cerebral Performance Category 3-5 at 2-6 months after cardiac arrest. Plasma samples were retrospectively analysed for GFAP, tau, and NFL. Serum NSE was analysed in clinical care. Prognostic performances were tested with the area under the receiver operating characteristics curve (AUC).
RESULTS
RESULTS
Of the 428 included patients, 328 were OHCA, and 100 were IHCA. At ICU admission, 12 h and 48 h post-cardiac arrest, GFAP predicted neurological outcome after OHCA with AUC (95% CI) 0.76 (0.70-0.82), 0.86 (0.81-0.90) and 0.91 (0.87-0.96), and after IHCA with AUC (95% CI) 0.77 (0.66-0.87), 0.83 (0.74-0.92) and 0.83 (0.71-0.95). At the same time points, tau predicted outcome after OHCA with AUC (95% CI) 0.72 (0.66-0.79), 0.75 (0.69-0.81), and 0.93 (0.89-0.96) and after IHCA with AUC (95% CI) 0.61 (0.49-0.74), 0.68 (0.56-0.79), and 0.77 (0.65-0.90). Adding the change in biomarker levels between time points did not improve predictive accuracy compared to the last time point. In a subset of patients, GFAP at 12 h and 48 h, as well as tau at 48 h, offered similar predictive value as NSE at 48 h (the earliest time point NSE is recommended in guidelines) after both OHCA and IHCA. The predictive performance of NFL was similar or superior to GFAP and tau at all time points after OHCA and IHCA.
CONCLUSION
CONCLUSIONS
GFAP and tau are promising biomarkers for neuroprognostication, with the highest predictive performance at 48 h after OHCA, but not superior to NFL. The predictive ability of GFAP may be sufficiently high for clinical use at 12 h after cardiac arrest.
Identifiants
pubmed: 38594704
doi: 10.1186/s13054-024-04889-0
pii: 10.1186/s13054-024-04889-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116Subventions
Organisme : EU Joint Programme - Neurodegenerative Disease Research
ID : 2019-03401
Informations de copyright
© 2024. The Author(s).
Références
Elmer J, Torres C, Aufderheide TP, Austin MA, Callaway CW, Golan E, et al. Association of early withdrawal of life-sustaining therapy for perceived neurological prognosis with mortality after cardiac arrest. Resuscitation. 2016;102:127–35.
doi: 10.1016/j.resuscitation.2016.01.016
pubmed: 26836944
pmcid: 4834233
Nolan JP, Sandroni C, Böttiger BW, Cariou A, Cronberg T, Friberg H, et al. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines 2021: post-resuscitation care. Resuscitation. 2021;161:220–69.
doi: 10.1016/j.resuscitation.2021.02.012
pubmed: 33773827
Humaloja J, Ashton NJ, Skrifvars MB. Brain injury biomarkers for predicting outcome after cardiac arrest. Crit Care. 2022;26(1):81.
doi: 10.1186/s13054-022-03913-5
pubmed: 35337359
pmcid: 8957160
Humaloja J, Lähde M, Ashton NJ, Reinikainen M, Hästbacka J, Jakkula P, et al. GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: a post hoc analysis of the COMACARE trial. Resuscitation. 2022;170:141–9.
doi: 10.1016/j.resuscitation.2021.11.033
pubmed: 34863908
pmcid: 8786666
Mattsson N, Zetterberg H, Nielsen N, Blennow K, Dankiewicz J, Friberg H, et al. Serum tau and neurological outcome in cardiac arrest. Ann Neurol. 2017;82(5):665–75.
doi: 10.1002/ana.25067
pubmed: 28981963
pmcid: 5725735
Huesgen KW, Elmelige YO, Yang Z, Chowdhury MAB, Gul S, Maciel CB, et al. Ultra-early serum concentrations of neuronal and astroglial biomarkers predict poor neurological outcome after out-of-hospital cardiac arrest-a pilot neuroprognostic study. Resusc Plus. 2021;7: 100133.
doi: 10.1016/j.resplu.2021.100133
pubmed: 34223394
pmcid: 8244405
Ebner F, Moseby-Knappe M, Mattsson-Carlgren N, Lilja G, Dragancea I, Undén J, et al. Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. Resuscitation. 2020;154:61–8.
doi: 10.1016/j.resuscitation.2020.05.016
pubmed: 32445783
Song H, Bang HJ, You Y, Park JS, Kang C, Kim HJ, et al. Novel serum biomarkers for predicting neurological outcomes in postcardiac arrest patients treated with targeted temperature management. Crit Care. 2023;27(1):113.
doi: 10.1186/s13054-023-04400-1
pubmed: 36927495
pmcid: 10022069
Klitholm M, Nørgaard Jeppesen A, Christensen S, Parkner T, Tybirk L, Kirkegaard H, et al. Neurofilament light chain and glial fibrillary acidic protein as early prognostic biomarkers after out-of-hospital cardiac arrest. Resuscitation. 2023;193:109983.
doi: 10.1016/j.resuscitation.2023.109983
pubmed: 37778613
Ashton NJ, Moseby-Knappe M, Benedet AL, Grötschel L, Lantero-Rodriguez J, Karikari TK, et al. Alzheimer disease blood biomarkers in patients with out-of-hospital cardiac arrest. JAMA Neurol. 2023;80(4):388–96.
doi: 10.1001/jamaneurol.2023.0050
pubmed: 36877496
pmcid: 9989959
Hoiland RL, Rikhraj KJK, Thiara S, Fordyce C, Kramer AH, Skrifvars MB, et al. Neurologic prognostication after cardiac arrest using brain biomarkers: a systematic review and meta-analysis. JAMA Neurol. 2022;79(4):390–8.
doi: 10.1001/jamaneurol.2021.5598
pubmed: 35226054
pmcid: 8886448
Wihersaari L, Reinikainen M, Furlan R, Mandelli A, Vaahersalo J, Kurola J, et al. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation. 2022;174:1–8.
doi: 10.1016/j.resuscitation.2022.02.024
pubmed: 35245610
Gul SS, Huesgen KW, Wang KK, Mark K, Tyndall JA. Prognostic utility of neuroinjury biomarkers in post out-of-hospital cardiac arrest (OHCA) patient management. Med Hypotheses. 2017;105:34–47.
doi: 10.1016/j.mehy.2017.06.016
pubmed: 28735650
Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004;62(8):1303–10.
doi: 10.1212/01.WNL.0000120550.00643.DC
pubmed: 15111666
Kaneko T, Kasaoka S, Miyauchi T, Fujita M, Oda Y, Tsuruta R, et al. Serum glial fibrillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest. Resuscitation. 2009;80(7):790–4.
doi: 10.1016/j.resuscitation.2009.04.003
pubmed: 19411130
Foerch C, Niessner M, Back T, Bauerle M, De Marchis GM, Ferbert A, et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem. 2012;58(1):237–45.
doi: 10.1373/clinchem.2011.172676
pubmed: 22125303
Liu G, Geng J. Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke. Hum Exp Toxicol. 2018;37(10):1048–53.
doi: 10.1177/0960327117751236
pubmed: 29308673
Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenström H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45(1):138–41.
doi: 10.1093/clinchem/45.1.138
pubmed: 9895354
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471–83.
doi: 10.1001/jamaneurol.2021.3671
pubmed: 34661615
Helwig K, Seeger F, Hölschermann H, Lischke V, Gerriets T, Niessner M, et al. Elevated serum glial fibrillary acidic protein (GFAP) is associated with poor functional outcome after cardiopulmonary resuscitation. Neurocrit Care. 2017;27(1):68–74.
doi: 10.1007/s12028-016-0371-6
pubmed: 28054291
Larsson IM, Wallin E, Kristofferzon ML, Niessner M, Zetterberg H, Rubertsson S. Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. Resuscitation. 2014;85(12):1654–61.
doi: 10.1016/j.resuscitation.2014.09.007
pubmed: 25260722
Levin H, Lybeck A, Frigyesi A, Arctaedius I, Thorgeirsdóttir B, Annborn M, et al. Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest. Crit Care. 2023;27(1):74.
doi: 10.1186/s13054-023-04355-3
pubmed: 36829239
pmcid: 9960417
Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11): e012799.
doi: 10.1136/bmjopen-2016-012799
pubmed: 28137831
pmcid: 5128957
Sandroni C, Cariou A, Cavallaro F, Cronberg T, Friberg H, Hoedemaekers C, et al. Prognostication in comatose survivors of cardiac arrest: an advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine. Resuscitation. 2014;85(12):1779–89.
doi: 10.1016/j.resuscitation.2014.08.011
pubmed: 25438253
Lissner Östlund E, Levin H, Nielsen N, Frigyesi A, Lybeck A. Neuron-specific enolase and long-term neurological outcome after OHCA—a validation study. Resuscitation. 2021;168:206–13.
doi: 10.1016/j.resuscitation.2021.09.001
pubmed: 34508799
Stammet P, Collignon O, Hassager C, Wise MP, Hovdenes J, Åneman A, et al. Neuron-specific enolase as a predictor of death or poor neurological outcome after out-of-hospital cardiac arrest and targeted temperature management at 33°C and 36°C. J Am Coll Cardiol. 2015;65(19):2104–14.
doi: 10.1016/j.jacc.2015.03.538
pubmed: 25975474
Streitberger KJ, Leithner C, Wattenberg M, Tonner PH, Hasslacher J, Joannidis M, et al. Neuron-specific enolase predicts poor outcome after cardiac arrest and targeted temperature management: a multicenter study on 1053 patients. Crit Care Med. 2017;45(7):1145–51.
doi: 10.1097/CCM.0000000000002335
pubmed: 28426467
Bogoslovsky T, Wilson D, Chen Y, Hanlon D, Gill J, Jeromin A, et al. Increases of plasma levels of glial fibrillary acidic protein, tau, and amyloid β up to 90 days after traumatic brain injury. J Neurotrauma. 2017;34(1):66–73.
doi: 10.1089/neu.2015.4333
pubmed: 27312416
pmcid: 5198034
Randall J, Mörtberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation. 2013;84(3):351–6.
doi: 10.1016/j.resuscitation.2012.07.027
pubmed: 22885094